In this prospective longitudinal study we aim to assess how immunologic and viral aspects of the human immunodeficiency virus (HIV) viral reservoir, established during early HIV infection and responsible for viral rebound at treatment interruption, evolve in individuals who start combination anti-retroviral therapy (cART) during acute seroconversion. Recently infected patients will be selected based on Fiebig staging for an in depth sampling protocol at different timepoints during a 2 year follow up period. Colonbiopsies, lymphnode resection, lumbar puncture, leucapheresis and repeated peripheral venous blood-draws will be performed. Immunological, virological and genome expression analysis will be performed on the gathered samples.
Study Type
OBSERVATIONAL
Enrollment
70
Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
RECRUITINGEvolution of virological and immunological parameters of the HIV reservoir in recently infected HIV positive patients that started treatment during acute seroconversion.
Virological, immunological and gene expression analysis on blood and tissue from in depth sampling.
Time frame: 10 years
Evolution of microbiome in recently infected HIV positive patients that started treatment during acute seroconversion.
Microbiome analysis on stoolsamples.
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.